Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Imugene plans to begin Phase 1 oncolytic virus technology clinical trials in 2020

Proactive Investors Monday, 21 October 2019
Imugene Ltd (ASX:IMU) is advancing its preliminary clinical development plan (CDP) for the proposed exclusive license of the patents covering the CF33 oncolytic virus technology, which is subject to  shareholders’ approval at an Extraordinary Meeting of Shareholders to be held on November 18, 2019. The CF33 oncolytic virus (OV) was developed in the lab of Professor Yuman Fong, an internationally recognised surgeon and scientist at City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases based in California. CF33 has been developed in two different constructs: one version of the OV is armed with an immune checkpoint inhibitor inserted in the virus, which is known as CheckVacc; and the other an unarmed construct, known as Vaxinia. It is planned by Imugene that two separate Phase 1 clinical trials will be conducted in 2020 to test a CheckVacc construct and a Vaxinia construct of the OV. CheckVacc Pre-clinical studies conducted at City of Hope by Professor Fong have shown encouraging results in triple negative breast cancer (TNBC) when CF33 is combined with an immune checkpoint inhibitor (ICI), specifically a PD-L1 inhibitor to yield CheckVacc. TNBC is an aggressive subtype of breast cancer affecting 20% of breast cancer patients with poor prognosis upon diagnosis of metastases, largely due to lack of effective targeted therapy. Immune check point inhibitors have shown efficacy in TNBC’s. The Phase 1 trial commencing in 2020 will be an open-label, dose-escalating, non-randomised, single-centre phase 1 study of CheckVacc administered intratumorally in patients with metastatic TNBC with injectable metastatic lesions. The purpose of the study will be to evaluate the safety and initial evidence of efficacy of the CF33-antiPDL1 combination oncolytic virus against TNBC. Vaxinia The impressive activity of the CF33 oncolytic virus Vaxinia has been demonstrated in multiple solid tumour types in validated in-vivo models of pancreatic, colorectal, lung, TNBC and colon cancers. Importantly, Vaxinia outperforms the industry leading OV’s from Amgen and Genelux. Vaxinia is more potent than its competitors and a strong advantage is the level of dosing required, at least in preclinical animal models, is much lower. The Phase 1 MAST (Mixed Advanced Solid Tumours) trial commencing in 2020 will be an FDA IND Imugene sponsored open-label, dose-escalating, non-randomised, multi-centre (including Australian hospitals) phase 1 study of Vaxinia administered intratumorally or intravenously in patients with solid tumours (lung, TNBC, melanoma, bladder, GI). The purpose of the study will be to evaluate the safety and initial evidence of efficacy of the CF33 Vaxinia oncolytic virus against solid tumours.

You Might Like

Recent related videos from verified sources

First new HIV strain identified in nearly 20 years: Study [Video]First new HIV strain identified in nearly 20 years: Study

ABBOTT PARK, ILLINOIS — A joint study by Abbott Laboratories and the University of Missouri has identified a new subtype of the HIV strain for the first time in 19 years. A press release from..

Credit: TomoNews US     Duration: 01:24Published

A Measles Type Virus Is Killing Thousands Of Seals [Video]A Measles Type Virus Is Killing Thousands Of Seals

As the planet warms, Arctic ice continues to thaw at a rapid rate, threatening sea life across the globe. A new study shows the disappearance of Arctic sea ice has allowed a deadly virus to spread..

Credit: Wochit     Duration: 00:38Published

Recent related news from verified sources

Cyclo Therapeutics Signs Agreement with Worldwide Clinical Trials to Conduct Pivotal Trial in Niemann-Pick Disease Type C

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for...
Business Wire

Seelos Therapeutics updates investors on 3Q drug development, plans studies for Sanfilippo syndrome, PTSD treatments

Seelos Therapeutics Inc (NASDAQ:SEEL) updated investors Friday on the progress of its drug pipeline during the third quarter, which included Food and Drug...
Proactive Investors

Tweets about this

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.